31 Mar 2024
Assets22.68
Total Income27.66
EBITDA5.26
Profit After Tax2.93
NET Worth15.06
Reserves and Surplus9.95
Total Borrowing2.86
At a glance
Updated 2026-09-09Speciality Medicines is a SME IPO with an issue size of ₹29.14 crore, proposed for listing on BSE SME. The offer opens on 20th Mar 2026 and closes on 24th Mar 2026. The issue structure includes a fresh issue of ₹27.28 crore.
Issue details
Listing atBSE SME
Issue typeBook Build Issue
Issue size₹29.14 Cr
Fresh issue₹27.28 Cr
Face value₹10
Price band₹117.00–₹124.00
Allotment25th Mar 2026
Listing30th Mar 2026
Grey market
GMP page ↗Latest GMP₹0.00
GMP / upper price0.00%
Est. listing₹124.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens20th Mar 2026
Closes24th Mar 2026
Allotment25th Mar 2026
Refund27th Mar 2026
Demat27th Mar 2026
Listing30th Mar 2026
Subscription demand
Full bidding ↗QIB96.24×
sHNI0.64×
bHNI2.24×
NII / HNI2.24×
Retail0.85×
Total2.27×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 2000 | ₹248,000 |
Company
Incorporated2021
Use of proceeds
| Object | Amount |
|---|---|
| Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat | ₹12.68 Cr |
| Product Registration in International Markets and Product Development for sale in international markets | ₹2.99 Cr |
| Funding for Marketing and Promotional Activities | ₹1.66 Cr |
| To Meet Working Capital Requirements | ₹8.00 Cr |
| General Corporate Purposes | ₹0.25 Cr |
| Issue Expenses | ₹3.57 Cr |
| Total | ₹29.14 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue36.93₹ Cr · -36.9% vs prior year
EBITDA6.51₹ Cr · -28.4% vs prior year
PAT6.06₹ Cr · -29.6% vs prior year
Assets45.57₹ Cr · +14.0% vs prior year
Net Worth36.47₹ Cr · +19.9% vs prior year
Borrowing4.81₹ Cr · -4.8% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2025
Assets39.98
Total Income58.54
EBITDA9.09
Profit After Tax8.61
NET Worth30.42
Reserves and Surplus23.98
Total Borrowing5.05
31 Oct 2025
Assets45.57
Total Income36.93
EBITDA6.51
Profit After Tax6.06
NET Worth36.47
Reserves and Surplus30.04
Total Borrowing4.81
KPIs
| KPI | Mar 31, 2025 | Oct 31, 2025 |
|---|---|---|
| ROE | 37.85% | 18.11% |
| ROCE | 33.39% | 16.68% |
| Debt / Equity | 0.17% | 0.13% |
| RoNW | 28.30% | 16.61% |
| PAT Margin | 14.77% | 16.49% |
| EBITDA Margin | 15.60% | 17.73% |
| Price to Book Value | 2.62 | 2.19 |
Valuation & shareholding
Pre-IPO EPS13.38
Post-IPO EPS11.82
Pre-IPO P/E9.27
Post-IPO P/E10.49
Promoter holding pre59.28%
Promoter holding post43.44%
Market cap₹108.94 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Speciality Medicines IPO | — | 10.49 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Curis Lifesciences IPO | — | 12.01 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat | ₹12.68 Cr |
| Product Registration in International Markets and Product Development for sale in international markets | ₹2.99 Cr |
| Funding for Marketing and Promotional Activities | ₹1.66 Cr |
| To Meet Working Capital Requirements | ₹8.00 Cr |
| General Corporate Purposes | ₹0.25 Cr |
| Issue Expenses | ₹3.57 Cr |
| Total | ₹29.14 Cr |
Registrar & lead managers
Registrar
Skyline Financial Services Pvt.Ltd.Lead managers
- Unistone Capital Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-09.
IPO UPDATE ALERTS
Register for IPO Updates →Track Speciality Medicines without missing an update
Register for subscription, GMP, allotment and listing notifications.